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Mechanism of Measles Virus–Induced Suppression
of Inflammatory Immune Responses
Although MV was the first pathogen reported to
induce immunosuppression, documented nearly 100
years ago (Von Pirquet, 1908), the lack of a suitable
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Thierry Walzer,* Rosine Tedone,* small animal model has impeded progress in under-
standing the mechanisms of MV-induced immune ab-Bruce Loveland,† Jean-Franc¸ois Nicolas,*
Chantal Rabourdin-Combe,* and Branka Horvat*‡§ normalities. Monkeys have been used (Auwaerter et al.,
1999), but their utilization is extremely restricted by lim-* INSERM U503, CERVI
Immunobiologie Fondamentale et Clinique ited supply and high cost. SCID mice grafted with human
PBL showed a reduced production of human IgG afterLyon, 69365
France MV infection (Tishon et al., 1996); nevertheless, this
model is not convenient for an accurate analysis of anti-†The Austin Research Institute
Heidelberg, VIC 3084 gen-specific responses due to the lack of MHC compati-
bility between murine stromal tissue and human PBL.Australia
Cotton rats, susceptible to MV infection, subsequently
develop immunosuppression (Niewiesk et al., 1997) but
compared to mice are genetically and immunologicallySummary
poorly characterized. Recently, MV infection of mice
expressing CD46, human cellular receptor of MV, wasMeasles virus (MV) causes profound immunosuppres-
reported to be associated with immunosuppressionsion, resulting in high infant mortality. The mechanisms
(Oldstone et al., 1999), though several other reports sug-are poorly understood, largely due to the lack of a
gested that MV proteins alone can inhibit in vitro immunesuitable animal model. Here, we report that particular
response (Karp et al., 1996; Schlender et al., 1996; Rava-MV proteins, in the absence of MV replication, could
nel et al., 1997). Although these studies confirmed thegenerate a systemic immunosuppression in mice
existence of MV-induced restraint of immune response,through two pathways: (1) via MV-nucleoprotein and
the importance of MV replication and the mechanismits receptor FcgR on dendritic cells; and (2) via virus
responsible for induction of immunosuppression in vivoenvelope glycoproteins and the MV-hemagglutinin
remains elusive.cellular receptor, CD46. The effects comprise reduced
In this report, we investigated the roles of MV proteinshypersensitivity responses associated with impaired
in the generation of immunosuppression in vivo. Twofunction of dendritic cells, decreased production of IL-
types of T cell–dependent inflammatory reactions were12, and the loss of antigen-specific T cell proliferation.
analyzed: delayed type hypersensitivity (DTH) to keyholeThese results introduce a novel model for testing the
limpet hemocyanin (KLH) mediated by CD41 T cellsimmunosuppressive potential of anti-measles vac-
(Grabbe and Schwarz, 1998), and contact hypersensitiv-cines and reveal a specific mechanism of MV-induced
ity (CHS) induced by epicutaneous exposure to the hap-modulation of inflammatory reactions.
ten dinitrofluorobenzene (DNFB) and mediated by CD81
T cells (Bour et al., 1995; Kehren et al., 1999). DendriticIntroduction
cells play the critical role in the initiation of these inflam-
matory responses (Grabbe and Schwarz, 1998). WeMeasles virus (MV) is responsible for an acute childhood
demonstrated that MV replication is not necessary fordisease that each year infects over 40 million individuals
the induction of immunosuppression and that inacti-and causes the death of more than 1 million, primarily in
vated MV efficiently suppresses hypersensitivity re-the developing world (Murray and Lopez, 1997). The high
sponses in mice, after the interaction of viral envelopemortality is associated with transitional MV-induced
proteins and nucleoprotein with their respective cellularimmunosuppression, enabling secondary infections that
receptors. These results suggest that a conventionalseverely complicate the course of the disease (Beckford
murine hypersensitivity model could be directly applica-et al., 1985; Griffin et al., 1994). Measles infection is
ble in testing the immunosuppressive effects of anti-followed by the ablation of delayed-type hypersensitivity
measles vaccines. Furthermore, they provide evidenceresponses to tuberculin (Von Pirquet, 1908; Tamashiro et
that MV proteins directly induce suppression of inflam-al., 1987) and impaired in vitro proliferation of peripheral
matory reactions and impair dendritic cell function andblood lymphocytes (PBL) (Hirsch et al., 1984) as well as
have important implications in understanding the patho-allospecific cytolytic activity (Galama et al., 1980). Many
genesis of MV-induced inhibition of immunity.immunological alterations observed during measles in-
fection also occur at lesser magnitude after vaccination
Resultsof children using attenuated MV (Fireman et al., 1969;
Hussey et al., 1996).
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sensitivity response was not limited by the genetics of
mice used, giving the same results with C57BL/6, BALB/
c, and 129/Sv (data not shown). Finally, hypersensitivity
reaction was suppressed when MV-UV was injected up
to 2 days before sensitizing with the hapten (data not
shown), demonstrating that inhibitory effect of MV could
largely exceed 6 hr. Moreover, the use of inactivated
virus excluded any infectious component to this inhibi-
tion of inflammatory responses and focused our atten-
tion on the role of viral proteins.
Effect of Measles Nucleoprotein
on Hypersensitivity Responses
We next studied the MV components responsible for
immunosuppression. Analysis of the MV-UV inocula by
ELISA showed that the standard dose of 5 3 106 pfu
of MV-UV contained 15 6 4 mg free NP, which could
participate in the inhibition of inflammatory reactions in
mice. We then tested whether purified recombinant NP
could bind murine dendritic cells and demonstrated an
efficient binding that could be blocked by mAb specific
to murine FcR (2.4G2) (Figure 2A). Similar results were
obtained with murine macrophages (data not shown).
As Paramixovirus nucleocapsids contain two structural
units, an N-terminal domain, which interacts directly with
RNA, and a C-terminal domain, which lies on the surface
of the assembled nucleocapsid, we then analyzed whether
the C-terminal part of NP (126 aa) could bind dendritic
cells. Similarly to NP, NPc bound dendritic cells isolated
from normal mice (Figure 2A) but not from gene-targeted
mice lacking Fc receptor (FcR2/2) (Figure 2B).
Mice were then injected with either purified recombi-Figure 1. Effect of UV-Inactivated MV on Hypersensitivity Re-
sponses nant NP or NPc and analyzed for hypersensitivity re-
Groups of five C57BL/6 mice were injected intraperitoneally with sponses (Figure 2). Similarly to MV-UV, recombinant NP,
different concentrations of purified MV-UV: 200 mg corresponding as well as NPc, significantly reduced by half mouse ear
to 5 3 106 pfu, (MV-UV1) or 40 mg corresponding to 106 pfu (MV- swelling, indicating that this protein, particularly its C-ter-
UV2), 200 mg of RSV-UV, corresponding to 5 3 106 pfu or the mock minal part, plays an important role in MV-induced immu-
preparation.
nosuppression (Figure 2B). The effect of NP was dose(A) Mice were sensitized 6 hr later with DNFB or left unsensitized
dependent: absent with 6 mg, reaching threshold withand challenged after 5 days with DNFB; results are expressed as
12 mg, and maximal with 25 mg of NP (data not shown).mean ear swelling (6 SD) at different time points after challenge.
(B) Mice were immunized 6 hr later with KLH in CFA or left unsensi- Both human and murine Fc receptors for IgG effi-
tized and challenged after 7 days by footpad injection of KLH in ciently bind measles NP on B cells (Ravanel et al., 1997),
PBS. Results expressed as mean footpad swelling (6 SD) are repre- as well as dendritic cells (Figures 2A and 2B), so we
sentative of three independent experiments. analyzed whether FcgR is directly involved in suppres-
sion. Fc receptor–deficient mice were injected intraperi-
toneally with either recombinant NP, NPc, or UV-inacti-
C57BL/6 mice were injected intraperitoneally with differ- vated MV. In contrast to C57BL/6 mice (Figure 2C) and
ent amounts of purified UV-inactivated MV (MV-UV) and heterozygote progeny of FcR2/2 crossed with C57BL/6
sensitized 6 hr later with either DNFB on ventral skin mice (data not shown), where NP and MV-UV inhibited
(Figure 1A) or KLH in CFA injected subcutaneously (Fig- CHS response, in FcR2/2 mice injection of NP, NPc, or
ure 1B), and ear or footpad swelling, respectively, was MV-UV had no effect (Figure 2D). We next investigated
measured after the challenge. The effect of MV was whether MV-UV and its nucleoprotein could modulate
compared to another negative strand Paramyxoviridae DTH to KLH in wild-type and FcR2/2 mice (Figures 2E and
RNA virus, respiratory syncytial virus (RSV), which in- 2F). While both MV-UV, NP, and NPc inhibited footpad
fects the human respiratory system. While MV-UV signif- swelling in wild-type mice, this effect was again absent
icantly inhibited the inflammatory mouse ear swelling in FcR2/2 mice. The immunosuppressive effect of MV pro-
response after challenge with DNFB, injection of the teins was equivalent to that of 1 mg of dexamethasone,
same number of RSV-UV particles did not give any effect which, contrary to MV-induced suppression, persisted
(Figure 1A), excluding the role of viral RNA. RSV-UV did in FcR-deficient mice, demonstrating that hypersensitiv-
not inhibit the DTH response to KLH either, but MV-UV ity in these mice could be suppressed by the other
reduced it by half (Figure 1B). In addition, similar results mechanism not requiring FcR (Figures 2E and 2F). These
were obtained with purified MV-UV (Edmonston strain) results indicate that an interaction of NP, particularly its
and with virus supernatant, as well as with two other C-terminal part NPc, with FcgR is critical for MV-induced
immunosuppression of inflammatory responses in vivo.MV strains, Halle´ and MA93F, and the inhibition of hyper-
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Figure 2. Measles NP Binds Dendritic Cells and Inhibits Hypersensitivity Responses
Binding of NP and NPc to DC purified from normal (A) or FcR-deficient mice (B). Cells were incubated with either NP in the absence or in the
presence of anti-FcR mAb 2.4G2 or with NPc, and binding was detected with biotinylated anti-NP mAb Cl.25 and FITC-conjugated streptavidin.
Mouse IgG2a-biotin was used as an isotype control to Cl.25. Hypersensitivity responses were analyzed in groups of five C57BL/6 mice (C
and E) or FcR2/2 mice (D and F), injected i.p. with the mock preparation, NP (100 mg), NPc (400 mg), 5 3 106 pfu of MV-UV or 1 mg of water-
soluble dexamethasone (dexa).
(C–D) Mice were sensitized 6 hr later with DNFB or left unsensitized and challenged after 5 days. Results are expressed as mean ear swelling
(6 SD) at different time points after challenge and are representative of three independent experiments.
(E–F) Alternatively, 6 hr after MV-UV or NP injection, mice were immunized with KLH-CFA, and DTH to KLH was assessed after 7 days by
footpad challenge with KLH in PBS. Footpad swelling shown as mean 6 SD was measured after 24 hr and is representative of two independent
experiments.
Effect of Measles Envelope Glycoproteins on CHS effect on the generation of CHS to DNFB was compared
with wild-type UV-inactivated MV and its correspondingThe MV envelope has two glycoproteins, hemagglutinin
(H) and fusion (F) protein. The human CD46 molecule, recombinant virus, EDtag-UV. Injection of MGV-UV re-
duced CHS response by half in both mouse strains (Fig-not expressed in mice, binds MV-H and is a cellular
receptor for MV-Edmondston strain (Dorig et al., 1993; ure 3). Similar results were obtained with 100 mg of NP
(data not shown). The suppressive effect of MGV-UVNaniche et al., 1993), as well as for some clinical isolates
(Manchester et al., 2000). To assess the role of H and was analogous to the effect of EDtag-UV and MV-UV in
normal C57BL/6 mice (Figure 3A), indicating that viralF protein in MV-induced immunosuppression, we used
transgenic mice ubiquitously expressing CD46 at levels H and F were not critical for the induction of suppression
in the absence of CD46. However, immunosuppressiveresembling those of human tissues (Thorley et al., 1997).
C57BL/6 and CD46 transgenic mice were injected with effect was not observed after injection of vesicular sto-
matitis virus (VSV-UV), excluding the role of VSV-G pro-UV-inactivated recombinant MV in which H and F were
replaced by vesicular stomatitis G protein (MGV): its tein as well as viral RNA in the MGV-UV induced sup-
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Figure 3. Effect of Measles Envelope Glycoproteins on Contact Hypersensitivity
Groups of five C57BL/6 mice (A) or CD46 transgenic mice (B) were injected with either the mock preparation or 5 3 106 pfu of UV-inactivated
viruses: MV-UV, MGV-UV, or EDtag-UV, and sensitized 6 hr later with DNFB or left unsensitized. Mice were challenged after 5 days, and
results expressed as mean ear swelling (6 SD) at different time points after challenge are representative of two independent experiments.
pression (data not shown). Furthermore, inactivated CHS occurred in CD46 transgenic but not wild-type mice
challenged with DNFB 2 weeks after MV-UV injectionwild-type MV and its recombinant virus EDtag entirely
abolished ear swelling responses in CD46 transgenic (Figure 4B), indicating that CD46 expression not only
strengthened but also lengthened the duration of themice (Figure 3B), demonstrating that the interaction be-
tween MV-H and CD46 significantly enhanced antiin- antiinflammatory effects of MV proteins. Finally, these
results indicate the important systemic therapeutic effi-flammatory effect.
cacy of MV proteins both in prevention and treatment
of inflammatory responses.Therapeutic Efficacy of MV Proteins
Given the prophylactic potential of MV proteins in the
induction of inflammatory responses, we analyzed their MV Proteins Induce an Impaired Capacity
of Antigen-Presenting Cells to Stimulateeffect on the effector phase of CHS. Mice were DNFB
sensitized and injected 5 days later with MV-UV. The Antigen-Specific T Cell Proliferation
Generation of CHS depends on the activity of CD81 Teffector phase was initiated by DNFB challenge 6 hr
(Figure 4A) and 2 weeks later (Figure 4B), and ear swell- cells (Bour et al., 1995; Kehren et al., 1999). Therefore,
we analyzed whether CHS inhibition in MV-UV injecteding was measured 24 hr after challenge. A single injec-
tion of MV-UV into sensitized C57BL/6 mice was suffi- mice is associated with impaired priming of antigen-
specific CD81 T cells in lymphoid organs. C57BL/6,cient to inhibit CHS, demonstrating that MV proteins
suppress the effector phase of CHS as well. Similar to CD46-transgenic, or FcR2/2 mice were injected with MV-
UV or NP and 6 hr later sensitized with DNFB. Lymphoidthe effect observed at sensitization phase (Figure 3B),
the injection of MV-UV into already sensitized CD46 cells recovered from regional draining lymph nodes 4
days later were tested for hapten-specific proliferativetransgenic mice completely inhibited ear swelling (Fig-
ure 4A), suggesting that CD46 expression increases the responses (Figure 5A). CD81 T lymphocytes from mock-
injected and sensitized mice responded vigorously toinhibitory effect of MV proteins. In addition, inhibition of
Figure 4. Therapeutic Efficacy of MV Proteins
Groups of five C57BL/6 or CD46 transgenic mice were sensitized with DNFB and injected 5 days later with either 5 3 106 pfu of MV-UV or
mock, or left unsensitized. Mice were ear-challenged 6 hr (A) and 2 weeks (B) after sensitization. Results are expressed as mean ear swelling
(6 SD) at 24 hr after challenge.
Measles Virus Proteins Suppress Immune Response
73
Figure 5. Impaired Capacity of APC from MV-UV- and NP-Injected Mice to Stimulate Antigen-Specific T Cell Proliferation
C57BL/6, CD46 transgenic, or FcR2/2 mice to be used as donors of CD81 T cells were injected with either 5 3 106 pfu of UV-inactivated MV,
the mock preparation, 100 mg of recombinant NP or PBS, as indicated. Donors of APC were either naive syngeneic mice (A) or mice that
received the same treatment as donors of CD81 T cells (B). Mice were sensitized with DNFB 6 hr after injection, for donors of T lymphocytes,
or left unsensitized for APC donors. Four days later, lymph nodes were collected from three mice of the same group, and cell cultures were
set up to measure the DNFB-specific proliferation of CD81 T lymphocytes. Irradiated splenocytes from either mock/PBS- or MV-UV/NP-injected
mice were coupled to either DNBS (A and B) or TNBS (A) and used as APC for CD81 T lymphocytes of either mock/PBS or MV-UV/NP-injected
and DNFB sensitized mice. Specific proliferation responses were determined after 3 days of culture by 3H-thymidine incorporation for 16 hr and
against DNBS modified syngenic spleen cells varied between 25,000 and 35,000 cpm. Results are expressed as a proliferation index, and
representative data of three independent experiments are shown as mean 6 SD (***P , 0.001, Student’s T-test).
DNBS-pulsed naive syngeneic antigen-presenting cells are in agreement with the capacity of MV proteins to
inhibit the effector phase of CHS (Figure 4A) and were(APC), but not to TNBS-coupled splenocytes, confirming
the antigen specificity of the response. However, prior reproduced with purified MV as well as with virus super-
natant. The inhibitory effect of MV proteins was absentsingle injection of C57BL/6 or CD46 transgenic mice with
either MV-UV or NP entirely abolished in vitro antigen- in FcR2/2 mice, highlighting the importance of the inter-
action of NP with FcR on APC in the pathogenesis of MV-specific proliferation of their CD81 T cells in response
to DNBS-coupled APC. Nevertheless, this inhibition did induced suppression. Altogether, these results indicate
that MV-UV and particularly NP impair the function ofnot occur in FcR2/2 mice injected with the same dose
of NP. These results demonstrate the important role of APC via FcgR, affecting not only the priming of naive
CD81 lymphocytes during sensitization but also the de-FcR in mediating the MV-induced defect in the priming
of CD81 T lymphocytes in vivo. velopment of the effector phase following secondary
antigen contact.We next investigated whether impaired APC capac-
ity modulated the proliferation of CD81 lymphocytes
primed normally in vivo. CD81 T lymphocytes obtained MV-UV Decreases the Percentage of IL-12-Producing
Dendritic Cells in Regional Lymph Nodesfrom mock-injected and DNFB-sensitized mice did not
proliferate when cultured with hapten-pulsed spleno- APC essential for priming of hypersensitivity responses
are dendritic cells (DC) (Grabbe and Schwarz, 1998). Ascytes (APC) from either MV-UV or NP injected CD46-
transgenic or wild-type mice (Figure 5B). These results DC have been identified as the major producers of IL-
Immunity
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Figure 6. Effect of MV-UV on the Intracellular Production of IL-12 by DC from Draining Lymph Nodes
Groups of three C57BL/6 (squares), CD46 transgenic (circles), or FcR2/2 mice were injected with either the mock (open symbols), or 5 3 106
pfu of UV-inactivated MV (solid symbols) and sensitized with DNFB 6 hr later. Draining lymph nodes were pooled at indicated time points
after MV-UV/mock injections. Enriched DC were incubated for 4 hr with monensin and subsequently stained for the surface expression of
MHC class II and CD11c, followed by cell permeabilization and anti-IL-12-PE intracellular staining.
(A) Representative profile obtained 24 hr after MV-UV/mock injection. MHC class II1 cells were analyzed for the percentage of CD11c1 IL-
121 double-positive cells. IL-12 staining was completely blocked if prior incubation with 0.5 mg of recombinant IL-12 was performed.
(B) Kinetics of intracellular IL-12 production. Results are expressed as the percentage of IL-121 cells within the MHC class II1 CD11c1
population at different time intervals after mock or MV-UV injection, as mean 6 SD for two experiments.
12 in lymph nodes (Sousa et al., 1997) and the secretion of DNFB-sensitized mice and transferred equal numbers
of IL-12 is associated with hypersensitivity responses of DC subcutaneously into immunocompetent recipi-
(Muller et al., 1995), we next examined whether MV pro- ents, which received 6 hr before the transfer, single i.p.
teins could modulate IL-12 production by DC after in injection of either mock or MV-UV. Four days after the
vivo hapten sensitization. CD46-transgenic, FcR2/2 mice, transfer, the recipients were challenged with DNFB (Fig-
and nontransgenic controls were either mock or MV-UV ure 7). As described previously with FITC-primed DC
injected and sensitized by DNFB 6 hr later. Draining (Kripke et al., 1990), transferred DNFB-primed DC in-
lymph nodes were harvested at regular time intervals, duce a significant CHS response in recipients (Figure
DC were highly enriched, giving the similar yields from 7A). However, when recipients were treated with MV-
each group, and analyzed for IL-12 production by intra- UV, the efficiency of transferred primed DC to induce
cellular staining and flow cytometry (Figure 6). In con- CHS response was reduced by half (Figure 7A). In con-
trast to FcR2/2 mice, where injection of MV-UV did not trast to wild-type DC, the transfer of immunity by DC
have any effect, in the other two types of mice the per- derived from sensitized FcR-deficient mice into the wild-
centage of MHC class II1 CD11c1 IL-121 DC decreased type was not influenced by MV-UV (Figure 7B), confirm-
up to 2-fold during the first 24 hr period, being more ing the role of FcR in the immunosuppressive effect of
reduced in CD46-transgenic (8.7%) than in wild-type MV and suggesting primed DC as a central target of MV
mice (12.3%) (Figure 6A). Notably, this reduction per- proteins. These results correlate with the absence of
sisted in CD46 transgenic mice after 48 hr (Figure 6B). immunosuppressive effect of MV-proteins in FcR-defi-
Further, no differences were observed in production of cient mice (Figure 2). Furthermore, when wild-type DC
TNF-a or IL-10 by the same cell populations 24 hr after were adoptively transferred from sensitized mice into
the treatment (data not shown). These data demon- FcR2/2 mice, inhibitory effect of MV-UV was established
strated that injection of MV-UV results in fewer IL-12 again (Figure 7C), suggesting that FcR-deficient envi-
producing lymph node DC. The effect was much more ronment in recipients is not a limiting factor, and empha-
pronounced and of a longer duration in CD46-transgenic sizing that FcR expression on DC is critical for the MV-
than in wild-type mice, suggesting a specific role for induced immunosuppression. Finally, transfer of DC
CD46. Finally, MV-UV did not affect the production of from CD46 transgenic mice into MV-UV injected wild-
IL-12 in FcR-deficient mice, indicating the important role type controls resulted with inhibition of hypersensitiv-
of FcR in the regulation this DC function. ity responses (Figure 7D). However, transfer of DC
from wild-type into MV-UV-injected CD46 transgenic
mice (Figure 7E) entirely abolished hypersensitivity re-Immunosuppressive Effect of MV Proteins Requires
sponses, indicating that in addition to DC some otherExpression of FcR on Dendritic Cells
cell type, when expressing CD46, may contribute theTo further analyze mechanism of MV-induced suppres-
sion, we purified DC that accumulated in lymph nodes MV-induced immunosuppressive effect.
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75
a novel assay to study the mechanism of the measles-
induced immunosuppression.
Few peripheral blood mononuclear cells in patients
with measles are infected (Esolen et al., 1993), indicating
that indirect mechanisms rather than a direct effect of
MV replication in lymphoid cells cause suppression.
Although more cells may be infected in peripheral
lymphoid organs of MV-infected patients, as it has been
demonstrated with HIV infection (Frankel et al., 1996),
in a recent CD46 transgenic mouse model, peripheral
MV infection was detected in less than 0.5% of spleno-
cytes (Oldstone et al., 1999). However, the role of nonin-
fectious virus in the generation of suppression was not
addressed in this murine model, and the lack of periph-
eral MV infection in our CD46 transgenic mice (Horvat
et al., 1996; Thorley et al., 1997; Evlashev et al., 2000)
prevented us from testing the effect of MV replication.
To gain more insight into the mechanism of immunosup-
pression, this study was focused on the role of MV pro-
teins in the absence of viral replication.
Our results reveal two pathways generating MV-
induced suppression of hypersensitivity: one requires an
interaction between measles NP and its cellular receptor
FcgR, whereas the other implicates virus envelope pro-
teins and the MV-hemagglutinin receptor, CD46. MV nu-
cleocapsid protein binds human and murine Fcg recep-
tors and inhibits human antibody production in vitro
(Ravanel et al., 1997). Here, we show that recombinant
NP has a broad immunosuppressive activity and is
equally able to inhibit T cell–dependent hypersensitivity
in mice. Similar to the effect of MV-UV, inhibition was
associated with the suppression of antigen-specific T
cell proliferation. Immunosuppressive effect of NP is
linked to the last 126 C-terminal amino acids, located
in the external part of measles nucleaocapsid, and was
completely absent in FcR2/2 mice, demonstrating the sig-
nificance of the NPc-FcR interaction. Liberation of free
Figure 7. Effect of MV-UV on Adoptively Transferred Immunity by NP could be expected after an injection of measles viri-
Dendritic Cells
ons into mice, and immunosuppressive effect of MV
Donor mice, either wild-type (A, C, and E), FcR2/2 (B), or CD46 trans-
supernatant in nontransgenic mice is most probablygenic (D) were DNFB sensitized and DC were purified 18 hr later
composed of scored effects of free NP and releasedfrom regional lymph nodes. Recipient mice, either wild-type (A, B,
virion-associated NP or its NPc fragment. These findingsand D), FcR2/2 (C), or CD46 transgenic (E), were injected i.p. with
either mock preparation or 5 3 106 pfu of MV-UV and received 6 hr are important to understand the pathogenesis of MV-
later 5 3 105 DC subcutaneously. Mice were ear-challenged after 4 induced suppression. During measles infection, the first
days with DNFB; results are expressed as mean ear swelling (6 SD) and most abundant antibodies produced in children are
at 24 hr (black bars) and 48 hr (white bars) after challenge.
those specific for NP (Graves et al., 1984). Anti-NP anti-
bodies are also detected after vaccination with live MV
vaccine (Norrby et al., 1975), indicating a release of MV-Discussion
nucleocapsid both during infection and after vaccination
and its availability to induce suppression. This NP-FcgRIn the present study, we demonstrate that MV proteins
interaction may provide a common immunosuppressiveinhibit two types of T cell–mediated inflammatory re-
pathway for MV strains that use either CD46 or recentlysponses in mice: CD8-dependent CHS to DNFB and
identified MV receptor SLAM (CDw152) (Tatsuo et al.,CD4-dependent DTH to KLH. Our results correlate with
2000). Indeed, both vaccinal and the wild-type strainsthe disappearance of DTH to tuberculin in children dur-
of MV inhibited hypersensitivity reactions in our study.ing and after measles infection (Von Pirquet, 1908; Ta-
Efficient immunization against measles is an importantmashiro et al., 1987), as well as with the important reduc-
public health issue; it is critical for eradication oftion of hypersensitive responses and cellular immunity
the disease, but requires additional improvements.after measles vaccination (Fireman et al., 1969; Hussey
Trials using a high-titered attenuated MV vaccine wereet al., 1996). In addition, suppression of antigen-specific
stopped because of unacceptable morbidity and mortal-proliferation of T lymphocytes in vitro, observed in our
ity (Garenne et al., 1991), and its pathogenesis remainsmurine model, mimics the lymphoproliferative defect
to be understood. Further identification of specific NPseen in patients with measles. Therefore, the murine
hypersensitivity model, described in this study, provides sequences responsible for the binding of FcR may allow
Immunity
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the development of the new generation of MV vaccines, UV (Fugier-Vivier et al., 1997). Our data further sug-
eventually deprived of immunosuppressive activity. gested the important role of FcR in MV-induced modula-
MV envelope proteins have been suggested to play tion of DC-mediated initiation of inflammatory reaction.
a role in limiting the capacity of mouse B cells to produce Abnormal maturation and differentiation of activated DC
MV-neutralizing antibodies (Fehr et al., 1998). In addi- has been recently demonstrated after in vitro infection
tion, the coexpression of MV-glycoproteins H and F on of human DC (Servet-Delprat et al., 2000). Whether the
UV-irradiated infected cells was reported to lead to a interaction of MV nucleoprotein with FcR could induce
contact-dependent inhibition of mitogen-induced prolif- a similar effect in vivo, or affect migration of DC, remains
eration by noninfected lymphoid cells and cell lines, to be determined. Finally, our adoptive transfer experi-
regardless of CD46 expression (Schlender et al., 1996; ments using CD46 transgenic mice as recipients sug-
Niewiesk et al., 1997). In contrast to these results, a gest the existence of some CD46-expressing cell popu-
soluble but unidentified factor secreted by MV-infected lation, which contributes, in addition to DC, to the
lymphocytes, suppressing antigen-driven proliferation induction of immunosuppression. Whether T lympho-
of uninfected T cells, has been proposed (Sun et al., cytes may be implicated in this effect, as it has recently
1998). Although our data do not exclude the existence been demonstrated that stimulation of CD46 could mod-
of an MV-induced soluble inhibitory factor, they show ulate human lymphocyte function (Astier et al., 2000),
the role of envelope proteins H and F in the inhibition remains to be analyzed. Altogether, these results sug-
of hypersensitivity but only in the presence of CD46. gest a more integral mechanism of MV-induced immu-
This requirement may define the specificity of the MV- nosuppression. Cytopathic viral replication during MV
envelope proteins in the inhibition of inflammatory re- infection (Bellini et al., 1994) or after vaccination could
sponses, which may be absent in the in vitro systems liberate MV proteins or their biologically active frag-
used by others. Whether in these models the recently ments, which may than interact with DC via Fc receptors,
identified MV receptor SLAM is implicated in the genera- leading to the altered DC function and reduced IL-12
tion of the immunosuppression needs to be analyzed. secretion. Additional viral replication in DC and potential
Our results demonstrate a significant decrease in den- involvement of some other cell populations, expressing
dritic cell IL-12 production from draining lymph nodes CD46, may contribute to this effect. Impaired DC func-
of mice hapten-sensitized after i.p. injection of MV-UV, tion is responsible for the defective T cell priming, re-
providing in vivo evidence of the systemic modulation duces their capacity to respond to foreign antigens and
of IL-12 production by MV proteins. Consistently with initiate the inflammatory response, which finally results
our data, infectious MV and MV-UV inhibit in vitro IL-12 in transient but profound immunosupression.
production by activated human dendritic cells (Fugier- The potential of MV proteins to modulate DC function
Vivier et al., 1997) and LPS-stimulated macrophages and affect both priming and the effector phase of hyper-
(Karp et al., 1996). Both CD46-dependent (Karp et al., sensitivity suggests their possible therapeutic applica-
1996) and FcgR-dependent (Sutterwala et al., 1997) tions, opening new avenues for clinical intervention. In-
mechanism of the inhibition of IL-12 production was deed, a marked improvement in symptoms of patients
demonstrated in human monocytes and murine macro- with atopic dermatitis during natural measles has often
phages, respectively. A reduction in IL-12, demon- been observed (Boner et al., 1985; Lin, 1986), and before
strated in our study, was evident in both CD46-trans- the development of pharmacological corticosteroids,
genic and wild-type mice but absent in FcR-deficient measles was exploited therapeutically in the treatment
mice, suggesting a role for measles NP-FcR interaction. of nephrotic syndrome (Blumberg and Cassady, 1947;
However, it was more profound and lasted longer in the Hutchins and Janeway, 1947) in spite of risks linked to
CD46 transgenic mice, indicating that MV-H interacting the infection. Further study of the immunoregulatory
with CD46 may cause a greater decrease in IL-12 pro- role(s) of purified MV proteins and their biologically ac-
duction and consequent defect in lymphocyte priming,
tive fragments, along with toxicology analyses, may
leading to the complete abolition of hypersensitivity.
open new possibilities of their specific application in
These results suggest existence of different molecular
immunomodulatory protocols aimed to treat T cell–cascades implicated in the regulation of IL-12 produc-
mediated inflammatory diseases.tion, induced by either FcR or CD46. Furthermore, IFN
a/b receptor-deficient mice (Muller et al., 1994) were
Experimental Proceduresimmunosuppressed at the same level as wild-type mice,
when injected with MV-UV (data not shown), indicating Mice
that IFN a/b system is not required for FcR-mediated C57BL/6 and BALB/c mice were purchased from IFFA CREDO (L’Ar-
immunosuppression. bresle, France). Transgenic mice ubiquitously expressing CD46
Dendritic cells play a critical role in both induction (Thorley et al., 1997) were crossed onto the C57BL/6 background.
Gene- targeted mice lacking FcR (FcgRII2/2 3 FcRg2/2, model 585-and elicitiation of hypersensitivity reactions and present
MM) were obtained from Taconic (USA), and used either as homozy-the cell population that is the most likely to be at the
gous or heterozygous, after one backcross in C57BL/6 background.site of virus entry and the early phase of infection. Our
Mice deficient for IFN a/b receptor (A129 line) (Muller et al., 1994)
results strongly suggest that DC are the major target of were generously provided by R.M. Zinkernagel. CD46 transgenic,
MV proteins, related to the profound defect in lympho- FcR2/2, and 129/Sv mice were bred in animal house of ENS de Lyon,
cyte priming. Consistent with these results, function of France.
human DC and their capacity to stimulate T cells was
shown to be impaired after MV infection in vitro (Fugier- Virus
Vivier et al., 1997; Grosjean et al., 1997; Schnorr et al., Measles virus Edmonston strain was obtained from ATCC (VR-24)
and wild-type MV strain, MA93F, was provided by Dr. F. Wild (Lyon,1997) and at lower extent after the contact with the MV-
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France). Recombinant MV in which H and F glycoproteins were nodes were pooled from three to four mice. Single cell suspensions
were prepared in RPMI 1640 medium (7.5% FCS) and 5 3 106 cells/replaced by G protein of vesicular stomatitis virus (MGV) (Spielhofer
et al., 1998), the molecularly cloned Edmonston strain (EDtag) (Ra- ml were layered on 2 ml of metrizamide (grade II, Sigma, 14.5 g/100
ml of medium) and centrifuged for 10 min at 600g. Cells at thedecke et al., 1995), respiratory syncytial virus (RSV) (group A, Long
strain), and vesicular stomatitis virus (VSV, Indiana strain) were used interface were collected, washed once, and analyzed. Purified cells
contained typically 75%–90% DC (CD11c1 B7-11 33D11 MHC-II1).for comparative studies. All viruses were propagated on Vero fibro-
blasts and harvested from infected cells when a strong cytopathic In some experiments, 90% pure DC (5 3 105) were adoptively trans-
ferred subcutaneusly into mice injected 6 hr previously with eithereffect developed. Mock preparation contained virus-free superna-
tant from uninfected Vero cells prepared under the same conditions. mock or MV-UV.
In some experiments, MV was additionally purified on a saccharose
gradient and gave results identical to nonpurified MV. All viruses Flow Cytometry
were inactivated by 30 min exposure at 48C to 254 nm UV irradiation For the detection of NP and NPc binding, 5 3 105 cells were incu-
and inactivation was confirmed by plaque assay. All virus stocks bated for 1 hr at 48C with either purified NP (6 mg) or NPc (30 mg)
were free of mycoplasma. in 100 ml of PBS (1% BSA and 0.1% NaN3). Cells were then washed
and incubated with anti-NP biotinylated mAb Cl.25, followed by
streptavidin conjugated to FITC staining and analyzed.Production of Recombinant and Viral NP and NPc
For the detection of intracellular cytokines, cell suspensions con-Recombinant MV nucleoprotein (525 aa) was produced and purified
taining enriched DC (106 cells/ml) were incubated with monensin (2from recombinant baculovirus AcNPVNP, and viral NP was purified
mM GolgiStop) at 378C in 7% CO2 for 4 hr, to block cytokine secretion.from Vero cells infected with MV, as described previously (Ravanel
FcgR was blocked with rat mAb 2.4G2, and cells were stained foret al., 1997).
surface markers using anti-MHC IA-b,d-FITC (Pharmingen) and anti-DNA corresponding to 126 aa of C-terminal end of NP was cloned
N418-biotin (anti-CD11c) followed by streptavidin tricolor (Catlag).into QIAexpress vector pQE-32 (Qiagen), containing 63Hist epitope
Intracellular cytokines were stained using the Cytofix/Cytoperm kittag and then inserted into the baculovirus genome using the pFast-
(Pharmingen) according to the manufacturer’s instructions and theBac1 vector and Bac-to-Bac Baculovirus Expression System (Life
following antibodies: C15.6-PE (anti-IL-12p40/p70), MP6-XT22-PETechnologies), according to the manufacturer’s instructions. Insect
(anti-TNF-a), JES5-16E3-PE (anti-IL-10), and isotype control (PE-SF9 cells were transfected with bacmid DNA containing NPc, and
R3-34 immunoglobulin). In some experiments, the preincubationrecombinant virus Bac-NPc was recovered from the supernatant.
with 0.5 mg of recombinant IL-12 (R&D Systems) was performedConfluent monolayers of High Five insect cells (Invitrogen) were
before staining with C15.6-PE antibody. All flow cytometry analysesinfected with Bac-NPc virus at a multiplicity of 1 PFU/cell. Infected
were carried out on a FACScan (Becton Dickinson).cells were harvested 3 days postinfection, cell pellets were lysed,
and NPc was purified according to the Qiagen protocol for high-
level expression and purification of 63His-tagged proteins (The T Cell Proliferation
QIAexpressionist). Inguinal, brachial, and axillary lymph nodes cells were collected 4
days after DNFB sensitizing. CD81 T lymphocytes were purified by
negative selection using magnetic beads coupled with anti-rat IgGAssay for Contact Hypersensitivity to DNFB
(H&L) as described (Horvat et al., 1996); obtained cell suspensionsCHS to DNFB was determined as described (Kehren et al., 1999).
contained more than 95% CD81 viable cells. The antigen-presentingIn brief, DNFB was diluted in acetone: olive oil (4:1) before use, and
cell population was obtained from splenocytes of unsensitized mice25 ml of 0.5% DNFB solution was applied to a shaved ventral skin
and irradiated at 1500 rad. APC were left untreated or pulsed with(sensitization phase). After 5 days, mice received 10 ml of a nonirri-
either DNBS or 2,4,6-trinitrofluorobenzene-sulfonic acid (TNBS) astant concentration of DNFB applied on both sides of the left ear
described (Kehren et al., 1999). In vivo DNFB-primed CD81 T cellsand the solvent alone on the right ear (effector phase). Ear thickness
(5 3 105/well) were cocultured in 96-well plates with 106 APC, whichwas monitored before challenge and every day after challenge for
were either DNBS or TNBS-pulsed or left untreated, in RPMI 16404 to 6 days, by a third experimenter blinded to sample identity. The
medium supplemented with 10% FCS, 10 mM HEPES, 2 mM glu-ear swelling was calculated as {(T-To) left ear} - {(T-To) right ear},
tamin, 5 3 1025M 2b-ME, and 50 mg/ml of gentamicin for 3 days atwhere T and To are ear thickness after and before challenge, respec-
378C, 7% CO2. Cell proliferation was assessed on day 3 by 3H thymi-tively.
dine incorporation for 16 hr. Results were expressed as proliferation
indices: (cpm of T cells cultured with hapten-pulsed spleen cells) 4Assay for Delayed-Type Hypersensitivity to KLH
(cpm of T cells cultured with untreated spleen cells).DTH response to KLH was measured by a conventional footpad
swelling assay. Mice were sensitized by the subcutaneous injection
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